In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Happens After the Device IPO?

This article was originally published in Start Up

Executive Summary

Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?

You may also be interested in...



Can a Hippo Save the IPO Market for Life Sciences?

A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.

Covidien Set to Compete in Vascular Business

Covidien, following the acquisition of Vnus Medical Technologies and Bacchus Vascular, is establishing a global business unit focused on vascular surgery.

Northstar Goes Supernova: Troubled Brain Stimulation Firm Plans Liquidation

The directors of Northstar Neuroscience, developer of the Renova cortical stimulation system, have elected to liquidate all assets and dissolve the company

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel